Takeda Pharmaceutical Co - ADR
TAK
Market Cap$45.27B
Close$
Earnings Call Q4 2023
May 9, 2024 - AI Summary
Takeda's fiscal year 2023 performance exceeded management guidance, with core revenue growth of 1.5% at constant exchange rates driven by Growth & Launch Products.
Core operating profit declined 13.3%, in line with guidance, due to loss of exclusivity for high-margin products and increased investment in R&D and data, digital, and technology (DD&T).
The company made significant progress in its pipeline, with three new therapies approved in the US and several life cycle management approvals.
Exclusive for Stockcircle Pro members
Sign up
$31.04
126.2% upside
Current Fair Value
126.2% upsideUndervalued by 126.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $45.27 Billion |
|---|---|
| Enterprise Value | $4.38 Trillion |
| Dividend Yield | $0.58916 (4.62919225318847%) |
| Earnings per Share | $46.05 |
| Beta | 0.26 |
| Outstanding Shares | 3,166,312,596 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 32.26 |
|---|---|
| PEG | -11.06 |
| Price to Sales | 0.01 |
| Price to Book Ratio | 0.01 |
| Enterprise Value to Revenue | 0.96 |
| Enterprise Value to EBIT | 6.06 |
| Enterprise Value to Net Income | 15 |
| Total Debt to Enterprise | 1.19 |
| Debt to Equity | 0.75 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Takeda Pharmaceutical Co
CEO: Christophe Weber